Cargando…

Oncolytic strategy using new bifunctional HDACs/BRD4 inhibitors against virus-associated lymphomas

Primary effusion lymphoma (PEL) caused by Kaposi sarcoma–associated herpesvirus (KSHV) is an aggressive malignancy with poor prognosis even under chemotherapy. Currently, there is no specific treatment for PEL therefore requiring new therapies. Both histone deacetylases (HDACs) and bromodomain-conta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jungang, Wang, Zhengyu, Phuc, Tran, Xu, Zhigang, Yang, Donglin, Chen, Zhengzhu, Lin, Zhen, Kendrick, Samantha, Dai, Lu, Li, Hong-yu, Qin, Zhiqiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879403/ https://www.ncbi.nlm.nih.gov/pubmed/36638143 http://dx.doi.org/10.1371/journal.ppat.1011089

Ejemplares similares

Mechanistic Insights into Chemoresistance Mediated by Oncogenic Viruses in Lymphomas
por: Chen, Jungang, et al.
Publicado: (2019)

Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy
por: Nakashima, Hiroshi, et al.
Publicado: (2015)

Identification of natural compounds tubercidin and lycorine HCl against small‐cell lung cancer and BCAT1 as a therapeutic target
por: Chen, Jungang, et al.
Publicado: (2022)

The Anti-COVID-19 Drug Remdesivir Promotes Oncogenic Herpesvirus Reactivation through Regulation of Intracellular Signaling Pathways
por: Chen, Jungang, et al.
Publicado: (2022)

Bifunctional HDAC Therapeutics: One Drug to Rule Them All?
por: Smalley, Joshua P., et al.
Publicado: (2020)

A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
por: Ramos, Louise, et al.
Publicado: (2023)

CPI-637 as a Potential Bifunctional Latency-Reversing Agent That Targets Both the BRD4 and TIP60 Proteins
por: Zheng, Tengyi, et al.
Publicado: (2021)

HDAC stimulates gene expression through BRD4 availability in response to IFN and in interferonopathies
por: Marié, Isabelle J., et al.
Publicado: (2018)

Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
por: Marchini, Antonio, et al.
Publicado: (2016)

HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma
por: Wang, Xiaoguang, et al.
Publicado: (2020)

Recent Update of HDAC Inhibitors in Lymphoma
por: Chen, I-Chung, et al.
Publicado: (2020)

Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine
por: Dan, Jia, et al.
Publicado: (2023)

Clinicopathological features and prediction values of HDAC1, HDAC2, HDAC3, and HDAC11 in classical Hodgkin lymphoma
por: Huang, Renhong, et al.
Publicado: (2018)

Recruitment of Brd3 and Brd4 to acetylated chromatin is essential for proinflammatory cytokine-induced matrix-degrading enzyme expression
por: Dai, Jin, et al.
Publicado: (2019)

ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response
por: Nagarajan, Sankari, et al.
Publicado: (2020)

Dual HDAC/BRD4 Inhibitors Relieves Neuropathic Pain by Attenuating Inflammatory Response in Microglia After Spared Nerve Injury
por: Borgonetti, Vittoria, et al.
Publicado: (2022)

Targeting Sphingosine Kinase by ABC294640 against Diffuse Intrinsic Pontine Glioma (DIPG)
por: Dai, Lu, et al.
Publicado: (2020)

Preparation data of the bromodomains BRD3(1), BRD3(2), BRD4(1), and BRPF1B and crystallization of BRD4(1)-inhibitor complexes
por: Hügle, Martin, et al.
Publicado: (2016)

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas
por: Zhang, Qing, et al.
Publicado: (2019)

Targeting BRD9 by I-BRD9 efficiently inhibits growth of acute myeloid leukemia cells
por: Zhou, Lixin, et al.
Publicado: (2021)

BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell
por: Deeney, Jude T., et al.
Publicado: (2016)

Bromodomain-containing subunits BRD1, BRD2, and BRD13 are required for proper functioning of SWI/SNF complexes in Arabidopsis
por: Jarończyk, Kamila, et al.
Publicado: (2021)

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021)

Methylation of BRD4 by PRMT1 regulates BRD4 phosphorylation and promotes ovarian cancer invasion
por: Liu, Yi, et al.
Publicado: (2023)

The Therapeutic Strategy of HDAC6 Inhibitors in Lymphoproliferative Disease
por: Cosenza, Maria, et al.
Publicado: (2018)

Pharmacological Targeting of Bcl-2 Induces Caspase 3-Mediated Cleavage of HDAC6 and Regulates the Autophagy Process in Colorectal Cancer
por: Yang, Donglin, et al.
Publicado: (2023)

BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis
por: Roberts, Thomas C., et al.
Publicado: (2017)

BRD2 Compartmentalizes the Accessible Genome
por: Xie, Liangqi, et al.
Publicado: (2022)

Eradication of metastatic melanoma through cooperative expression of RNA-based HDAC1 inhibitor and p73 by oncolytic adenovirus
por: Schipper, Holger, et al.
Publicado: (2014)

Progress of oncolytic virotherapy for neuroblastoma
por: Chen, Xiao-Tong, et al.
Publicado: (2022)

Regulation of programmed cell death by Brd4
por: Hu, Jinfeng, et al.
Publicado: (2022)

Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma
por: Vann, Kendra R., et al.
Publicado: (2022)

Transactivation of human endogenous retroviruses by tumor viruses and their functions in virus-associated malignancies
por: Chen, Jungang, et al.
Publicado: (2019)

Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications
por: Uusi-Kerttula, Hanni, et al.
Publicado: (2015)

Ribonucleotide Reductase Inhibitor 3-AP Induces Oncogenic Virus Infected Cell Death and Represses Tumor Growth
por: Dai, Lu, et al.
Publicado: (2018)

tBRD-1 and tBRD-2 regulate expression of genes necessary for spermatid differentiation
por: Theofel, Ina, et al.
Publicado: (2017)

Increased expression of BRD4 isoforms long (BRD4-L) and short (BRD4-S) promotes chemotherapy resistance in high-grade serous ovarian carcinoma
por: Drumond-Bock, Ana Luiza, et al.
Publicado: (2023)

Bifunctional catalysis
por: Dixon, Darren J
Publicado: (2016)

Retinoblastoma protein as an intrinsic BRD4 inhibitor modulates small molecule BET inhibitor sensitivity in cancer
por: Ding, Donglin, et al.
Publicado: (2022)

Targeting BRD9 for Cancer Treatment: A New Strategy
por: Zhu, Xiuzuo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dal81pbc9ua0r4vo0fjh0vdcld